Activation of PPARγ by a Natural Flavonoid Modulator, Apigenin Ameliorates Obesity-Related Inflammation Via Regulation of Macrophage Polarization

Xiujing Feng,Dan Weng,Feifei Zhou,Young D. Owen,Haohan Qin,Jingfa Zhao,Wen Yu,Yahong Huang,Jiajia Chen,Haijian Fu,Nanfei Yang,Dianhua Chen,Jianxin Li,Renxiang Tan,Pingping Shen
DOI: https://doi.org/10.1016/j.ebiom.2016.06.017
IF: 11.205
2016-01-01
EBioMedicine
Abstract:PPARγ has emerged as a master regulator of macrophage polarization and is the molecular target of the thiazolidinedione drugs. Here we show that apigenin binds and activates PPARγ by acting as a modulator. Activation of PPARγ by apigenin blocks p65 translocation into nuclei through inhibition of p65/PPARγ complex translocation into nuclei, thereby decreasing NF-κB activation and favoringM2 macrophage polarization. In HFD and ob/ob mice, apigenin significantly reverses M1 macrophage into M2 and reduces the infiltration of inflammatory cells in liver and adipose tissues, as well as decreases the levels of pro-inflammatory cytokines, thereby alleviating inflammation. Strikingly, apigenin reduces liver and muscular steatosis, decreases the levels of ALT, AST, TC and TG, improving glucose resistance obviously. Unlike rosiglitazone, apigenin does not cause significant weight gain, osteoporosis et al. Our findings identify apigenin as a modulator of PPARγ and a potential lead compound for treatment of metabolic disorders.
What problem does this paper attempt to address?